Publications of Martin Gengenbacher
All genres
Journal Article (21)
2017
Journal Article
2 (4), e00057-17 (2017)
Integration of Metabolomics and Transcriptomics Reveals a Complex Diet of Mycobacterium tuberculosis during Early Macrophage Infection. mSystems
Journal Article
7 (1), 8853 (2017)
NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. Scientific Reports
Journal Article
47, pp. 8 - 16 (2017)
BCG — old workhorse, new skills. Current Opinion in Immunology 2016
Journal Article
7 (3), e00679-16 (2016)
Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis. mBio
Journal Article
18 (5), pp. 364 - 368 (2016)
Post-exposure vaccination with the vaccine candidate Bacillus Calmette–Guérin ΔureC::hly induces superior protection in a mouse model of subclinical tuberculosis. Microbes and Infection 2015
Journal Article
18 (1), pp. 96 - 108 (2015)
Absolute Proteome Composition and Dynamics during Dormancy and Resuscitation of Mycobacterium tuberculosis. Cell Host & Microbe
Journal Article
211 (11), pp. 1831 - 1841 (2015)
The Recombinant BCG ΔureC::hly Vaccine Targets the AIM2 Inflammasome to Induce Autophagy and Inflammation. The Journal of Infectious Diseases
Journal Article
16 (1), 34 (2015)
Comprehensive insights into transcriptional adaptation of intracellular mycobacteria by microbe-enriched dual RNA sequencing. BMC Genomics 2014
Journal Article
210 (12), pp. 1928 - 1937 (2014)
Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-Guérin ΔureC::hly Vaccine's Superior Protection Against Tuberculosis. The Journal of Infectious Diseases
Journal Article
5 (3), e01262-14 (2014)
Dietary Pyridoxine Controls Efficacy of Vitamin B6-Auxotrophic Tuberculosis Vaccine Bacillus Calmette-Guérin ΔureC::hly Δpdx1 in Mice. mBio
Journal Article
13 (5), pp. 619 - 630 (2014)
The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Review of Vaccines
Journal Article
2 (2), MGM2-0020-2013 (2014)
Mycobacterium tuberculosis in the Proteomics Era. Microbiology Spectrum 2013
Journal Article
8 (11), e78966 (2013)
The Tuberculosis Vaccine Candidate Bacillus Calmette-Guérin ΔureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in Mice. PLoS One
Journal Article
57 (10), pp. 4689 - 4698 (2013)
Improved Efficacy of Fosmidomycin against Plasmodium and Mycobacterium Species by Combination with the Cell-Penetrating Peptide Octaarginine. Antimicrobial Agents and Chemotherapy
Journal Article
13 (5), pp. 602 - 612 (2013)
The Mtb Proteome Library: A Resource of Assays to Quantify the Complete Proteome of Mycobacterium tuberculosis. Cell Host & Microbe
Journal Article
1 (2), pp. 120 - 138 (2013)
Nonclinical Development of BCG Replacement Vaccine Candidates. Vaccines
Journal Article
57 (4), pp. 1648 - 1653 (2013)
Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2012
Journal Article
23 (6), pp. 900 - 907 (2012)
Recombinant live vaccine candidates against tuberculosis. Current Opinion in Biotechnology
Journal Article
36 (3 Sp. Iss. SI), pp. 514 - 532 (2012)
Mycobacterium tuberculosis: success through dormancy. FEMS MICROBIOLOGY REVIEWS
Journal Article
56 (4), pp. 1735 - 1743 (2012)
Antigen 85C Inhibition Restricts Mycobacterium tuberculosis Growth through Disruption of Cord Factor Biosynthesis. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY